

Listing of the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1- 36 (cancelled)

Claim 37 (previously presented): A method of treating or managing sexual dysfunction in a mammal in need of treatment which comprises administering on an as-needed basis to the mammal a therapeutically effective amount of dapoxetine or a pharmaceutically acceptable salt thereof, wherein the sexual dysfunction is premature ejaculation, wherein the mammal is a human male, and wherein said administration of dapoxetine is effective for treating or managing premature ejaculation in the absence of priming doses.

Claim 38 (original): The method of claim 37, wherein dapoxetine is administered immediately prior to, to about 12 hours prior to a sexual activity.

Claim 39 (original): The method of claim 37, wherein dapoxetine is administered immediately prior to, to about 8 hours prior to a sexual activity.

Claim 40 (previously presented): A method of treating or managing sexual dysfunction in a mammal in need of treatment which comprises administering on an as-needed basis to the mammal a therapeutically effective amount of dapoxetine or a pharmaceutically acceptable salt thereof, wherein the sexual dysfunction is premature ejaculation, wherein the mammal is a human male, wherein dapoxetine is administered immediately prior to, to about 4 hours prior to a sexual activity and wherein said administration of dapoxetine is effective for treating or managing premature ejaculation in the absence of priming doses.

Claim 41 (original): The method of claim 37, wherein dapoxetine is administered immediately prior to, to about 3 hours prior to a sexual activity.

Claim 42 (original): The method of claim 37, wherein dapoxetine is administered immediately prior to a sexual activity.

Claims 43-50 (cancelled)

Claim 51 (previously presented): A method of treating premature ejaculation in a human male which comprises administering orally to the human male about 0.01 mg to about 200 mg of dapoxetine or a pharmaceutically acceptable salt thereof immediately prior to, to about 4 hours

prior to a sexual activity, wherein said administration of dapoxetine is effective for treating premature ejaculation in the absence of priming doses.

Claim 52 (previously presented): A method of treating premature ejaculation in a human male which comprises administering orally to the human male about 0.01 mg to about 200 mg of dapoxetine or a pharmaceutically acceptable salt thereof immediately prior to, to about 3 hours prior to a sexual activity, wherein said administration of dapoxetine is effective for treating premature ejaculation in the absence of priming doses.

Claim 53 (previously presented): A method of treating premature ejaculation in a human male which comprises administering orally to the human male about 0.01 mg to about 200 mg of dapoxetine or a pharmaceutically acceptable salt thereof about 30 minutes to about 3 hours prior to a sexual activity, wherein said administration of dapoxetine is effective for treating premature ejaculation in the absence of priming doses.

Claim 54 (previously presented): A method of treating premature ejaculation in a human male which comprises administering orally to the human male about 0.01 mg to about 200 mg of dapoxetine or a pharmaceutically acceptable salt thereof immediately prior to a sexual activity, wherein said administration of dapoxetine is effective for treating premature ejaculation in the absence of priming doses.

Claim 55 (cancelled)